Karra Nour, Sharon Amir, Massalha Eias, Fefer Paul, Maor Elad, Guetta Victor, Ben-Zekry Sagit, Kuperstein Rafael, Matetzky Shlomi, Beigel Roy, Segev Amit, Barbash Israel M
Division of Cardiology, Leviev Heart and Vascular Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel.
The Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
J Clin Med. 2024 Aug 25;13(17):5027. doi: 10.3390/jcm13175027.
Transcatheter aortic valve replacement (TAVR) is indicated for severe aortic stenosis patients with a prohibitive surgical risk. However, its use has been expanding in recent years to include intermediate- and low-risk patients. Thus, registry data describing changes in patient characteristics and outcomes are needed. The aim of this study was to analyse the temporal changes in patient profiles and clinical outcomes of all-comer TAVR. Baseline characteristics and VARC-3 outcomes of 1632 consecutive patients undergoing TAVR between 2008 and 2021 were analysed. The annual rate of TAVR increased from 30 procedures in 2008-2009 to 398 in 2020-2021. Over the follow-up period, patient age decreased from 85 ± 4 to 80 ± 6.8 ( < 0.001) and the STS score decreased from 5.9% to 2.8% ( < 0.001). Procedural characteristics significantly changed, representing a shift into a minimally invasive approach: adoption of local anaesthesia (none to 48%, < 0.001) and preference of transfemoral access (74% in 2011-2012 vs. 94.5% in 2020-2021, < 0.001). The rates of almost all procedural complications decreased, including major vascular and bleeding complications, acute kidney injury (AKI) and in-hospital heart failure. There was a striking decline in rates of complete atrioventricular block (CAVB) and the need for a permanent pacemaker (PPM). PPM rates, however, remain high (17.8%). Thirty-day and one-year mortality significantly declined to 1.8% and 8.3%, respectively. Multivariable analysis shows that AKI, bleeding and stroke are strong predictors of one-year mortality ( < 0.001). The TAVR procedure has changed dramatically during the last 14 years in terms of patient characteristics, procedural aspects and device maturity. These shifts have led to improved procedural safety, contributing to improved short- and long-term patient outcomes.
经导管主动脉瓣置换术(TAVR)适用于手术风险极高的重度主动脉瓣狭窄患者。然而,近年来其应用范围不断扩大,已涵盖中低风险患者。因此,需要有描述患者特征和预后变化的登记数据。本研究的目的是分析所有接受TAVR患者的特征和临床预后的时间变化。分析了2008年至2021年间连续接受TAVR的1632例患者的基线特征和VARC-3结局。TAVR的年手术例数从2008 - 2009年的30例增加到2020 - 2021年的398例。在随访期间,患者年龄从85±4岁降至80±6.8岁(P<0.001),胸外科医师协会(STS)评分从5.9%降至2.8%(P<0.001)。手术特征发生了显著变化,呈现出向微创方法的转变:采用局部麻醉(从无到48%,P<0.001)以及更倾向于经股动脉入路(2011 - 2012年为74%,2020 - 2021年为94.5%,P<0.001)。几乎所有手术并发症的发生率都有所下降,包括主要血管和出血并发症、急性肾损伤(AKI)以及院内心力衰竭。完全性房室传导阻滞(CAVB)的发生率和永久起搏器(PPM)的植入需求显著下降。然而,PPM的发生率仍然很高(17.8%)。30天和1年死亡率分别显著降至1.8%和8.3%。多变量分析表明,AKI、出血和中风是1年死亡率的强预测因素(P<0.001)。在过去14年中,TAVR手术在患者特征、手术方式和器械成熟度方面发生了巨大变化。这些转变提高了手术安全性,有助于改善患者的短期和长期预后。